{"id":389942,"date":"2021-12-20T00:00:00","date_gmt":"2021-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2021-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-forecast-g7-2021\/"},"modified":"2026-04-16T11:22:02","modified_gmt":"2026-04-16T11:22:02","slug":"dlsfim0003-2021-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2021-biopharma-chronic-obstructive-pulmonary-disease-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist\/inhaled corticosteroid fixed-dose combinations (LABA\/ICSFDCs) toward LABA\/long-acting muscarinic antagonist (LAMA) FDCs and even LABA\/LAMA\/ICSFDCs, but current and emerging generics will have a significant impact on this trend. Some branded generic and generic LABA\/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the near future; because cost remains a significant driver, we expect competition from these generics to affect the uptake of both LABA\/LAMA and LABA\/LAMA\/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease, and the development of novel drug classes continues.\u00a0<strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How will markets react to the launch \/ uptake of generic LABA\/ICSFDCs and tiotropium? Will there be significant country-to-country differences in the uptake of these generics?<\/li>\n<li>Will LABA\/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA\/LAMA\/ICSFDCs threaten these agents?<\/li>\n<li>What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?<\/li>\n<li>Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION\u00a0<\/strong><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-389942","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389942\/revisions"}],"predecessor-version":[{"id":576331,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389942\/revisions\/576331"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}